FDA clearance Jan 4, 2023 FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek Dec 7, 2022 FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy Dec 1, 2022 Sofie Biosciences to Begin Trial of Fluorine-Labeled PET Diagnostic Imaging Agent for GI Cancers Nov 22, 2022 Legend Biotech to Launch CAR T-Cell Therapy Trial for Small Cell Lung Cancer, Neuroendocrine Tumors Nov 15, 2022 FDA Approves ImmunoGen's Elahere for Folate Receptor Alpha-Positive Ovarian Cancer Sep 27, 2022 Thermo Fisher Gets FDA OK for CDx Test to Guide Use of Lilly Drug in Lung, Thyroid Cancers Sep 6, 2022 Monte Rosa to Begin Phase I/II Trial of MRT-2359 in MYC-Driven Solid Cancers Aug 19, 2022 Verismo Therapeutics Files IND to Study Cell Therapy in Advanced Mesothelin-Expressing Solid Tumors Aug 5, 2022 FDA Approves Enhertu for HER2-Low Metastatic Breast Cancer Jul 21, 2022 MD Anderson, Obsidian Therapeutics to Launch First-In-Human Trial of Engineered TILs for Melanoma Jul 15, 2022 Pfizer's Xalkori Gets FDA Approval for ALK-Positive Inflammatory Myofibroblastic Tumors May 25, 2022 Angle Gets FDA Clearance for Breast Cancer Cell Isolation System Jan 25, 2022 Lyell Immunopharma's IND for T-Cell Receptor Therapy Gets FDA Clearance Jan 10, 2022 23andMe Gains FDA Clearance for Direct-to-Consumer Prostate Cancer Genetic Risk Test Jan 7, 2022 FDA Clears Jubilant Therapeutics' IND Allowing for LSD1/HDAC6 Inhibitor Clinical Trial Dec 29, 2021 Regor Therapeutics to Begin US CDK2/4/6 Inhibitor Study for HR-Positive, HER2-Negative Breast Cancer Dec 17, 2021 Lyell Immunopharma Receives IND Clearance for Phase I Trial of CAR T-Cell Therapy for ROR1-Expressing TNBC, NSCLC Dec 9, 2021 FDA Approves Thermo Fisher Scientific Oncomine Dx Assay as CDx for Janssen Lung Cancer Drug Nov 2, 2021 Ikena Oncology to Launch Trial of TEAD Inhibitor in Biomarker-Selected Cancers Oct 27, 2021 Precigen to Study Anti-ROR1 CAR T-Cell Therapy for TNBC, Hematologic Cancers Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer